Baird Financial Group
ACAD icon

Baird Financial Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Baird Financial Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Buy
+9,163
New +$202K ﹤0.01% 1822
2025
Q2 		– Sell
-90,864
Closed -$1.51M – 1766
2025
Q1 		$1.51M Buy
+90,864
New +$1.65M ﹤0.01% 1052

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Baird Financial Group's ACAD Position: Q2 2026 in Review

Baird Financial Group opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 9,163 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #1822 among its holdings. This is a return to the name: Baird Financial Group previously reported a position in ACAD as recently as Q1 2025.

Baird Financial Group first reported a position in ACAD in Q1 2025 and has held it in 2 quarters since. The position peaked at $1.51M in Q1 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Baird Financial Group held 9,163 shares of Acadia Pharmaceuticals worth $232K as of Q2 2026.
  • Acadia Pharmaceuticals was a new Baird Financial Group position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1822 holding.
  • Baird Financial Group first reported a position in Acadia Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • Baird Financial Group's Acadia Pharmaceuticals position peaked at $1.51M in Q1 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.